Latest News About Eli Lilly And Company

Here are the latest publicly reported updates on Eli Lilly and Company.

• Lilly reports ongoing momentum in obesity and diabetes programs, with recent updates on tirzepatide (Zepbound) and related weight-management initiatives. This includes FDA pathways and continued pipeline progress.[2][5]
• The company has been active in strategic acquisitions and partnerships to expand its portfolio, including recent activity around obesity care access and related platforms for employers, as well as completed or announced acquisitions in 2024–2025.[3][2]
• Corporate leadership disclosures show executives’ compensation details for 2025, reflecting executive incentives tied to pipeline progress and financial performance.[2]
• Market coverage highlights Lilly’s broader performance in 2024–2025, with attention to product performance (Mounjaro, Zepbound, Verzenio, Jardiance) and pipeline momentum, along with manufacturing investments to support tirzepatide and other programs.[4][5][3]
• For the most current press releases and official statements, Lilly’s own newsroom is the best primary source, with recent updates posted under their press releases and news pages.[5][7]

If you’d like, I can pull a recent press release or summarize a specific topic (e.g., tirzepatide status with regulators, obesity drug access programs, or one of Lilly’s recent acquisitions) with exact quotes and dates. Please tell me which area you want the latest details on.